Amgen

Open: 256.96 Close: 256.04 Change: -0.92

Don't invest in Amgen before reading this automated analysis produce by an AI.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, Amgens, inhibitor, acquisition, Therapeutics, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

FTC Pauses Challenge to Amgens $27.8 billion deal for Horizon Therapeutics. FTC to consider whether the agency should settle the case. Amgen committed to renounce any sales tactics that FTC officials believe illegal.

Today's News

FTC Pauses Challenge to Amgens $27.8 billion deal for Horizon Therapeutics. FTC to consider whether the agency should settle the case. Amgen said it has committed to renounce any sales tactics that FTC officials believe are illegal. FTC, Amgen break off settlement talks over Horizon Therapeutics sale. FTC and Amgen had been in settlement talks, but those talks have ended. Amgen is progressing the largest and broadest global KRAS G12C  inhibitor development program exploring multiple combination regimens. Amgen has submitted MAAs in Colombia, Malaysia and Saudi Arabia. Director, Quality Assurance - amgen. director, quality assurance - will ensure product quality standards are met in compliance with Amgen and regulatory requirements. Horizon Therapeutics shares jumped more than 5% early trading Monday after FTC said it would suspend its challenge to Amgens acquisition of the drug maker. FTC pulled back one of its efforts to block Amgens $28 billion acquisition of Horizon. FTC may be prioritizing a potential settlement with Amgen that we believe increases the probability of closing the Horizon acquisition. FTC sued to block the acquisition in May, saying the deal would let Amgen entrench the monopoly positions of Horizon treatments for two serious conditions. Amgen to discuss application for lumakras® (sotorasib) for the treatment of kras g12c-positive nsclc at fda advisory committee meeting. Amgen is progressing the largest and broadest global KRAS G12C  inhibitor development program. Amgen Short Interest Graph (3 months) Percentage of shares that are sold short for Amgen has declined since its last report. Amgens peer group average for short interest as a percentage of float is 3.21%. Amgen is proud to join forces with the American Heart Association on the “Lower Your LDL Cholesterol Now™” initiative. Nearly half of those who have experienced a heart attack or stroke did not know their cholesterol levels. Amgen presents late-breaking phase 2 olpasiran data at esc 2023. #WorldLungCancerDay. Amgen is progressing the largest and broadest global KRAS G12C  inhibitor development program exploring multiple combination regimens. Amgen has submitted MAAs in Colombia and Saudi Arabia. Amgen Filters Principal IS Architect - R&D Informatics (US Remote) Amgen Sa 4.9 amgen Sa Job In Thousand Oaks, CA Or Remote. Global Marketing Director will play a vital role in the launch of bemarituzumabab, a first-class FGFR2b inhibitor. The MCO team is responsible for timely and accurate implementation of discounts for contracted customers at Amgen. Responsible for ensuring compliance against applicable Commercial contracts.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, Amgens, inhibitor, acquisition, Therapeutics, and the most common words in the summary are: amgen, stock, job, market, report, news, data, . One of the sentences in the summary was: Amgen committed to renounce any sales tactics that FTC officials believe illegal.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #job #market #report #news #data.